Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

GreenLight Biosciences Holdings (GRNA)

1.475   0.075 (5.36%) 11-28 10:00
Open: 1.38 Pre. Close: 1.4
High: 1.485 Low: 1.38
Volume: 53,173 Market Cap: 224(M)

Technical analysis

as of: 2022-11-28 9:48:59 AM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 1.98     One year: 2.42
Support: Support1: 1.09    Support2: 0.9
Resistance: Resistance1: 1.7    Resistance2: 2.07
Pivot: 1.63
Moving Average: MA(5): 1.3     MA(20): 1.71
MA(100): 2.33     MA(250): 5.72
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 29.7     %D(3): 20.3
RSI: RSI(14): 40
52-week: High: 15.8  Low: 1.09
Average Vol(K): 3-Month: 434 (K)  10-Days: 387 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ GRNA ] has closed above bottom band by 37.3%. Bollinger Bands are 6.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.42 - 1.43 1.43 - 1.43
Low: 1.22 - 1.23 1.23 - 1.23
Close: 1.39 - 1.4 1.4 - 1.41

Company Description

GreenLight Biosciences Holdings, a biotechnology company, manufactures and sells ribonucleic acid (RNA) products for human health and agriculture applications. Its products for human health include mRNA vaccines and therapeutics; and agricultural RNA products to protect honeybees and crops. The company was founded in 2008 and is headquartered in Medford, Massachusetts.

Headline News

Tue, 22 Nov 2022
Finance Stocks Lead Highs Tuesday; Markets Rise - InvestorsObserver

Wed, 16 Nov 2022
Facilitating antibody-drug and vaccine development with CRISPR/Cas editing tools - News-Medical.Net

Wed, 09 Nov 2022
GreenLight Biosciences Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress - GlobeNewswire

Fri, 04 Nov 2022
Site-specific CRISPR-based mitochondrial DNA manipulation is limited by gRNA import | Scientific Reports -

Thu, 03 Nov 2022
Researchers Find DNA Changes Created by Gene Editing in SCD |... - Sickle Cell Anemia News

Tue, 01 Nov 2022
How to design your CRISPR gene editing experiments - SelectScience

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 152 (M)
% Held by Insiders 7.948e+007 (%)
% Held by Institutions 45.3 (%)
Shares Short 2,400 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.5072e+008
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -3
Return on Assets (ttm) 803.6
Return on Equity (ttm) -92.4
Qtrly Rev. Growth 4.17e+006
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth -18.5
Operating Cash Flow 0 (M)
Levered Free Cash Flow -137 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 2.02e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.